In our study, we hypothesized that combination of FGFR4 inhibitor BLU-554 and CXCR2 inhibitor SB265610 had any effect on HCC metastasis enhanced by HOXB5 overexpression. Here, CXCR2 is linked to hepatocellular carcinoma.